InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,267.84
(
-0.74%
)
US TECH 100
18,152.00
(
-0.42%
)
Dow Jones
39,065.26
(
-1.53%
)
Brent Oil
81.24
(
-0.09%
)
Bitcoin
67,730.46
(
-0.29%
)
Post# of 251927
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119686
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 09/01/2015 10:23:58 AM

Tuesday, September 01, 2015 10:23:58 AM

Post# of 251927
BMY/ABBV—FDA grants priority review for Empliciti (a/k/a elotuzumab) in second-line MM:

http://finance.yahoo.com/news/u-food-drug-administration-accepts-113000934.html

The exact PDUFA date isn’t given, but it should be on or around 3/1/16.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up